At week 16 , similar proportions of patients receiving placebo ( 35 % ) , apremilast 20 mg twice a day ( 28 % ) , and apremilast 30 mg twice a day ( 34 % ) met the American College of Rheumatology criteria for 20 % improvement in disease activity ( the primary efficacy end point ) .